Hemoglobinopathies Market to Reach USD 25.68 Billion by 2032, Fueled by Gene Therapy Advances and Rising Newborn Screening Programs.

Innovations in gene editing, expanding global diagnostic infrastructure, and strong government initiatives are driving the hemoglobinopathies market’s projected 11.56% CAGR through 2032, according to SNS Insider.

Austin, June 02, 2025 (GLOBE NEWSWIRE) — Hemoglobinopathies Market Size & Growth Analysis:

According to SNS Insider, the global hemoglobinopathies market is projected to grow from USD 9.63 billion in 2023 to USD 25.68 billion by 2032, registering a robust CAGR of 11.56% during the forecast period. Key factors fueling this growth include increased awareness, expanded newborn screening programs, and significant investment in innovative gene therapies and advanced diagnostics.

Hemoglobinopathies—such as sickle cell disease (SCD), thalassemia, and other hemoglobin variants—remain a pressing global health issue, particularly in regions with high consanguinity rates and limited healthcare infrastructure.

Get a Sample Report of Hemoglobinopathies Market@ https://www.snsinsider.com/sample-request/6511

U.S. Market Outlook

The U.S. hemoglobinopathy market, valued at USD 2.58 billion in 2023, is anticipated to expand to USD 6.66 billion by 2032, growing at a CAGR of 11.18%. The United States controlled over 26.78% of the world’s market in 2023. Federal and state programs in minority populations have improved access to genetic testing, disease-modifying therapies, and public health services. The recent FDA approvals of gene-editing treatments like Casgevy and Lyfgenia are milestone achievements in the therapeutic paradigm.

Hemoglobinopathies Market Report Scope

Report Attributes	Details
Market Size in 2024	US$ 9.63 billion
Market Size by 2032	US$ 25.68 billion
CAGR	CAGR of 11.56% From 2025 to 2032
Base Year	2024
Forecast Period	2025-2032
Historical Data	2021-2023
Key Segments	By Type (Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants) By Diagnosis (Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants) By Therapy (Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants)

Segment Highlights

By Type:

Sickle Cell Disease (SCD) dominated the market in 2023 with a combined market share of 57.40%. SCD is most prevalent among African, Middle Eastern, and South Asian populations. Governments in North America and Sub-Saharan Africa are ramping up screening and awareness initiatives to reduce disease burden. The treatment landscape continues to evolve with the development in gene therapy and drugs such as crizanlizumab and voxelotor.

By Diagnosis:

SCD diagnosis segment held 51.08% of the market in 2023. Advances in diagnostic methods—hemoglobin electrophoresis, DNA-based, and high-performance liquid chromatography (HPLC)—have facilitated early diagnosis by means of neonatal and community health programs. The World Health Organization (WHO) states that early diagnosis by means of new-born screening can avert up to 70% of deaths in children with the condition up to the age of five. Prenatal and preimplantation genetic diagnostics are increasing in developed economies.

By Therapy:

Other Hemoglobin (Hb) Variants Therapy had the largest share of 63.25% in 2023. The segment includes alpha and beta thalassemia, Hb C, and Hb E therapies, prevalent in Southeast Asia, the Mediterranean, and the Middle East. Growth is driven by the availability of therapies such as blood transfusions, iron chelation, and bone marrow transplantation. National initiatives—China’s prenatal thalassemia screening and India’s National Health Mission—are raising awareness and treatment availability. Future growth is expected to arise from emerging therapies such as gene replacement and CRISPR-Cas9 genome editing.

Need Any Customization Research on Hemoglobinopathies Market, Enquire Now@ https://www.snsinsider.com/enquiry/6511

Regional Insights

North America dominated the global hemoglobinopathies market in 2023 with a 38.62% market share, driven by aggressive R&D expenditure by the NIH and FDA, universal insurance for genetic testing, and well-established healthcare infrastructure. The U.S. dominates the world in the adoption of curative therapies, with commercialization of FDA-approved therapy expected in early 2024. Newborn screening in Canada for SCD and thalassemia is incorporated in provincial healthcare systems, encouraging early intervention rates.

Europe remains a priority market, with harmonized nationwide screening programs and registries offering access for research and therapy in nations like Italy, Greece, and the UK.

The Asia-Pacific, particularly India, Thailand, and Indonesia, is experiencing enhancement through national control programs of hemoglobinopathies. India’s recent inclusion of thalassemia screening under its Universal Health Coverage program is set to substantially boost early diagnosis.

Key Hemoglobinopathies Companies Profiled in the Report

• Sangamo Therapeutics Inc.
• Global Blood Therapeutics Inc.
• bluebird bio Inc.
• Emmaus Life Sciences Inc.
• Pfizer Inc.
• Novartis AG
• Prolong Pharmaceuticals LLC
• Bioverativ Inc.
• Gamida Cell
• Celgene Corporation
• other players

Recent Developments

Indian Council of Medical Research (ICMR) launched a national registry in April 2024 to screen hemoglobinopathies and offer genetic counseling to high-risk patients. In February 2024, public-private partnerships for access were extended to crizanlizumab (Adakveo) in Sub-Saharan Africa.

Buy a Single-User PDF of Hemoglobinopathies Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/checkout/6511

Table of Contents – Major Key Points

1. Introduction

2. Executive Summary

3. Research Methodology

4. Market Dynamics Impact Analysis

5. Statistical Insights and Trends Reporting

6. Competitive Landscape

7. Hemoglobinopathies Market by Type

8. Hemoglobinopathies Market by Diagnosis

9. Hemoglobinopathies Market by Therapy

10. Regional Analysis

11. Company Profiles

12. Use Cases and Best Practices

13. Conclusion

CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.